Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -15.00K | 0.00 | -58.00K | -52.00K | -519.00K | -395.00K |
EBITDA | -24.91M | -13.64M | -34.19M | -7.64M | -35.30M | -27.14M |
Net Income | -18.87M | -13.70M | -34.36M | -35.60M | -35.82M | -27.53M |
Balance Sheet | ||||||
Total Assets | 25.35M | 19.79M | 12.19M | 39.67M | 69.09M | 101.79M |
Cash, Cash Equivalents and Short-Term Investments | 24.63M | 18.67M | 11.24M | 39.13M | 63.67M | 95.03M |
Total Debt | 0.00 | 0.00 | 0.00 | 203.00K | 0.00 | 0.00 |
Total Liabilities | 14.46M | 5.38M | 4.03M | 3.70M | 4.07M | 7.01M |
Stockholders Equity | 10.89M | 14.41M | 8.16M | 35.97M | 65.02M | 94.79M |
Cash Flow | ||||||
Free Cash Flow | -32.83M | -21.15M | -25.81M | -25.13M | -31.99M | -33.09M |
Operating Cash Flow | -32.82M | -21.15M | -25.73M | -22.88M | -31.50M | -32.06M |
Investing Cash Flow | 7.44M | -4.42M | 8.88M | 26.96M | 10.75M | -42.56M |
Financing Cash Flow | 19.67M | 27.97M | 20.90M | -139.00K | 695.00K | 92.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $48.51M | ― | -121.65% | ― | -0.71% | -169.29% | |
51 Neutral | $23.50M | ― | -36.31% | ― | 15.73% | 51.00% | |
47 Neutral | $19.51M | ― | -167.57% | ― | 127.51% | 71.16% | |
46 Neutral | C$194.85M | -4.28 | -8.56% | 2.84% | 13.52% | -1.74% | |
39 Underperform | $22.08M | ― | -134.15% | ― | ― | 95.48% | |
36 Underperform | $23.81M | ― | -39.78% | ― | ― | 84.17% | |
33 Underperform | $21.69M | ― | -112.99% | ― | ― | 57.93% |
On March 4, 2025, CalciMedica announced new data from a post-hoc analysis of the Phase 2 CARDEA trial, highlighting Auxora’s potential in reducing mortality among patients with severe COVID-19 pneumonia and acute kidney injury (AKI). The analysis revealed a 62.7% relative reduction in mortality for Auxora-treated patients compared to placebo, indicating a significant therapeutic benefit. This data underscores the potential of CRAC channel inhibition in treating AKI and supports ongoing clinical trials, which may enhance CalciMedica’s positioning in the biopharmaceutical industry.